



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

September 2021





© 2021 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2021 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

September 2021

N = 7448



Health Authority	Male	Female	All
FRASER	1471	454	1925
INTERIOR	443	104	547
NORTHERN	141	79	220
VANCOUVER COASTAL	3326	433	3759
VANCOUVER ISLAND	790	168	958
	6171	1238	7409
		Unknown/not stated:	39
		Total:	7448

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (September 2016 - September 2021)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (September 2016 - September 2021)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (September 2016 - September 2021)






1.5 BC-CfE Enrolment: New Antiretroviral Participants
(September 2016 - September 2021)






1.6 Percent Distribution of Active Participants by CD4 Count (September 2016 - September 2021)






1.7 Percent Distribution of Inactive Participants by CD4 Count (September 2016 - September 2021)






1.8 Active and Inactive Participants (September 2016 - September 2021)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (September 2016 - September 2021)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (September 2016 - September 2021)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(September 2016 - September 2021)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (September 2016 - September 2021)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(September 2016 - September 2021)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (September 2016 - September 2021)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(September 2016 - September 2021)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (September 2016 - September 2021)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(September 2016 - September 2021)






1.18 Baseline CD4 for Antiretroviral First Starts (September 2016 - September 2021)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (September 2016 - September 2021)






1.20 Cumulative Resistance Testing Results by Resistance Category (September 2016 - September 2021)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (September 2016 - September 2021)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2021
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	30	4	0	4	1	820	4	<40	4
1988	30	5	0	5	3	610	5	<40	3
1989	28	53	1	54	27	530	49	<40	3
1990	27	54	1	55	32	510	54	<40	3
1991	27	37	3	40	23	620	38	<40	3
1992	27	60	5	65	31	660	60	<40	3
1993	26	123	14	137	92	565	132	<40	3
1994	25	72	11	83	50	560	76	<40	3
1995	25	126	18	144	89	510	129	<40	3
1996	23	317	42	359	217	600	329	<40	3
1997	21	272	33	305	201	590	283	<40	3
1998	20	186	42	228	157	560	205	<40	3
1999	20	155	41	196	123	520	177	<40	3
2000	20	120	26	146	97	610	134	<40	3
2001	19	117	25	142	98	621	129	<40	3
2002	18	122	26	148	101	600	132	<40	3
2003	18	138	28	166	102	620	154	<40	3
2004	17	151	36	187	123	570	173	<40	3
2005	16	181	43	224	147	670	202	<40	3
2006	15	168	39	207	134	605	180	<40	3
2007	14	234	49	283	203	620	258	<40	3
2008	13	281	61	342	231	670	307	<40	3
2009	12	300	67	367	253	630	333	<40	3
2010	11	263	68	331	232	640	298	<40	3
2011	10	323	69	392	250	700	334	<40	3
2012	9	270	60	330	221	700	301	<40	3
2013	8	259	62	321	219	670	284	<40	3
2014	7	270	52	322	204	705	281	<40	3
2015	6	277	44	321	217	700	286	<40	3
2016	5	258	53	311	214	685	275	<40	3
2017	4	212	30	242	174	663	220	<40	3
2018	3	183	56	239	163	710	216	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2021
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	2	229	45	274	212	615	260	<40	3
2020	1	187	52	239	173	650	215	<40	3
2021	0	170	37	207	174	580	198	<40	3
Total:		6177	1239	7416					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2020	7358	774	2227	<40	1729	610
FEB-2020	7329	776	1882	<40	1417	620
MAR-2020	7387	768	1628	<40	1207	620
APR-2020	7408	770	767	<40	577	600
MAY-2020	7397	776	1186	<40	892	600
JUN-2020	7368	784	1558	<40	1148	620
JUL-2020	7333	794	1918	<40	1437	610
AUG-2020	7254	791	1848	<40	1332	630
SEP-2020	7233	784	1735	<40	1243	620
OCT-2020	7265	776	1782	<40	1309	630
NOV-2020	7340	763	1858	<40	1284	610
DEC-2020	7347	752	1542	<40	1085	630
JAN-2021	7384	746	1942	<40	1387	630
FEB-2021	7377	748	1787	<40	1273	630
MAR-2021	7432	743	2016	<40	1425	620
APR-2021	7417	746	1828	<40	1318	636
MAY-2021	7453	742	1869	<40	1295	630
JUN-2021	7457	738	1880	<40	1326	610
JUL-2021	7468	741	1821	<40	1309	640
AUG-2021	7476	740	1981	<40	1295	630
SEP-2021	7448	749	1762	<40	1163	630

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2020	635	185	70	354	46	435
FEB-2020	675	173	71	<40	58	480
MAR-2020	632	188	50	<40	32	415
APR-2020	611	204	28	116	22	555
MAY-2020	630	187	42	<50	30	490
JUN-2020	662	181	56	<40	46	480
JUL-2020	729	161	72	<40	56	625
AUG-2020	819	142	75	<40	65	470
SEP-2020	871	137	93	<40	71	610
OCT-2020	866	178	87	<40	75	570
NOV-2020	794	192	78	<40	63	510
DEC-2020	798	187	65	<40	55	420
JAN-2021	782	203	73	<40	56	525
FEB-2021	795	199	69	<40	56	510
MAR-2021	780	251	89	<40	70	630
APR-2021	813	258	73	<40	58	615
MAY-2021	791	277	72	<40	64	540
JUN-2021	790	270	65	57	47	540
JUL-2021	789	279	52	102	35	530
AUG-2021	797	275	53	<40	38	645
SEP-2021	841	232	65	<40	41	610

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2020	7328	635	10	12	183	155	18	13903
FEB-2020	7295	675	12	19	141	172	-33	13939
MAR-2020	7358	632	14	23	210	152	63	13975
APR-2020	7382	611	12	8	158	127	24	14000
MAY-2020	7375	630	10	15	130	135	-7	14025
JUN-2020	7345	662	9	9	125	149	-30	14042
JUL-2020	7308	729	15	12	160	189	-37	14074
AUG-2020	7222	819	18	11	168	240	-86	14094
SEP-2020	7193	871	19	8	229	241	-29	14115
OCT-2020	7226	866	20	13	223	176	33	14136
NOV-2020	7310	794	12	11	245	155	84	14162
DEC-2020	7325	798	10	13	205	190	15	14191
JAN-2021	7363	782	14	9	204	159	38	14211
FEB-2021	7355	795	15	13	186	190	-8	14235
MAR-2021	7409	780	15	24	203	156	54	14272
APR-2021	7396	813	13	9	165	172	-13	14297
MAY-2021	7427	791	14	14	178	143	31	14326
JUN-2021	7444	790	7	15	186	175	17	14352
JUL-2021	7451	789	9	12	170	163	7	14373
AUG-2021	7450	797	16	12	171	166	-1	14395
SEP-2021	7416	841	11	9	170	197	-34	14424

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2020	60	6758	484	56	7358	0.82%	91.85%	6.58%	0.76%	100.00%
FEB-2020	59	6735	477	58	7329	0.81%	91.90%	6.51%	0.79%	100.00%
MAR-2020	60	6790	487	50	7387	0.81%	91.92%	6.59%	0.68%	100.00%
APR-2020	61	6814	483	50	7408	0.82%	91.98%	6.52%	0.67%	100.00%
MAY-2020	60	6806	481	50	7397	0.81%	92.01%	6.50%	0.68%	100.00%
JUN-2020	59	6774	484	51	7368	0.80%	91.94%	6.57%	0.69%	100.00%
JUL-2020	61	6753	471	48	7333	0.83%	92.09%	6.42%	0.65%	100.00%
AUG-2020	70	6676	457	51	7254	0.96%	92.03%	6.30%	0.70%	100.00%
SEP-2020	85	6640	456	52	7233	1.18%	91.80%	6.30%	0.72%	100.00%
OCT-2020	107	6645	462	51	7265	1.47%	91.47%	6.36%	0.70%	100.00%
NOV-2020	162	6673	456	49	7340	2.21%	90.91%	6.21%	0.67%	100.00%
DEC-2020	180	6657	461	49	7347	2.45%	90.61%	6.27%	0.67%	100.00%
JAN-2021	205	6681	452	46	7384	2.78%	90.48%	6.12%	0.62%	100.00%
FEB-2021	226	6652	448	51	7377	3.06%	90.17%	6.07%	0.69%	100.00%
MAR-2021	249	6669	463	51	7432	3.35%	89.73%	6.23%	0.69%	100.00%
APR-2021	275	6644	454	44	7417	3.71%	89.58%	6.12%	0.59%	100.00%
MAY-2021	299	6641	465	48	7453	4.01%	89.11%	6.24%	0.64%	100.00%
JUN-2021	326	6614	471	46	7457	4.37%	88.70%	6.32%	0.62%	100.00%
JUL-2021	354	6598	470	46	7468	4.74%	88.35%	6.29%	0.62%	100.00%
AUG-2021	381	6581	472	42	7476	5.10%	88.03%	6.31%	0.56%	100.00%
SEP-2021	398	6540	463	47	7448	5.34%	87.81%	6.22%	0.63%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine															
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All														
JAN-2020	2	8%	3402	47%	2	8%	3226	45%	0	0%	34	0%	0	0%	1	0%	9	38%	1024	14%	13	54%	2963	41%	22	92%	3763	52%
FEB-2020	3	8%	3351	47%	3	8%	3179	45%	0	0%	33	0%	0	0%	1	0%	16	44%	1169	16%	17	47%	2825	40%	33	92%	3781	53%
MAR-2020	5	14%	3325	46%	5	14%	3160	44%	1	3%	34	0%	0	0%	1	0%	20	56%	1326	18%	11	31%	2719	38%	30	83%	3855	54%
APR-2020	6	24%	3298	46%	5	20%	3137	43%	1	4%	35	0%	0	0%	0	0%	8	32%	1402	19%	11	44%	2637	37%	19	76%	3888	54%
MAY-2020	1	4%	3272	45%	0	0%	3111	43%	0	0%	36	0%	0	0%	0	0%	13	54%	1481	21%	11	46%	2595	36%	23	96%	3914	54%
JUN-2020	5	29%	3242	45%	5	29%	3080	43%	0	0%	33	0%	0	0%	0	0%	4	24%	1585	22%	8	47%	2517	35%	12	71%	3921	55%
JUL-2020	6	19%	3199	45%	4	13%	3039	42%	2	6%	32	0%	0	0%	0	0%	14	44%	1695	24%	12	38%	2420	34%	26	81%	3942	55%
AUG-2020	3	15%	3149	45%	2	10%	2990	42%	0	0%	31	0%	0	0%	0	0%	11	55%	1759	25%	6	30%	2313	33%	17	85%	3913	55%
SEP-2020	3	14%	3121	44%	2	10%	2960	42%	0	0%	31	0%	0	0%	0	0%	13	62%	1868	26%	5	24%	2224	32%	18	86%	3927	56%
OCT-2020	2	10%	3121	44%	2	10%	2944	41%	0	0%	29	0%	0	0%	0	0%	12	57%	1971	28%	7	33%	2135	30%	19	90%	3961	56%
NOV-2020	7	27%	3164	44%	3	12%	2934	41%	1	4%	30	0%	0	0%	0	0%	11	42%	2063	29%	8	31%	2077	29%	19	73%	3990	56%
DEC-2020	3	10%	3151	44%	3	10%	2895	40%	0	0%	29	0%	0	0%	0	0%	14	48%	2144	30%	12	41%	2020	28%	26	90%	4011	56%
JAN-2021	2	10%	3153	44%	1	5%	2880	40%	0	0%	28	0%	0	0%	0	0%	12	60%	2220	31%	6	30%	1962	27%	18	90%	4045	56%
FEB-2021	2	8%	3135	43%	2	8%	2843	39%	0	0%	27	0%	0	0%	0	0%	16	67%	2298	32%	6	25%	1899	26%	22	92%	4061	56%
MAR-2021	8	22%	3140	43%	7	19%	2832	39%	0	0%	24	0%	0	0%	0	0%	23	62%	2368	33%	6	16%	1858	26%	29	78%	4111	57%
APR-2021	2	8%	3137	43%	2	8%	2802	39%	0	0%	25	0%	0	0%	0	0%	17	68%	2422	33%	6	24%	1791	25%	23	92%	4104	57%
MAY-2021	7	24%	3150	43%	3	10%	2784	38%	0	0%	22	0%	0	0%	0	0%	15	52%	2498	34%	10	34%	1759	24%	22	76%	4132	57%
JUN-2021	4	15%	3137	43%	3	12%	2741	38%	0	0%	23	0%	0	0%	0	0%	17	65%	2575	35%	5	19%	1698	23%	22	85%	4154	57%
JUL-2021	3	14%	3126	43%	2	10%	2707	37%	0	0%	23	0%	0	0%	0	0%	14	67%	2630	36%	4	19%	1659	23%	18	86%	4174	57%
AUG-2021	1	5%	3109	43%	1	5%	2667	36%	0	0%	23	0%	0	0%	0	0%	16	73%	2668	36%	5	23%	1634	22%	21	95%	4193	57%
SEP-2021	4	14%	3085	42%	2	7%	2621	36%	1	3%	22	0%	0	0%	0	0%	20	69%	2713	37%	5	17%	1590	22%	25	86%	4187	57%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		saquinavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	0 0%	2 0%	0 0%	910 37%	6 86%	1466 59%	1 14%	96 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2020	0 0%	2 0%	1 11%	873 36%	8 89%	1454 60%	0 0%	96 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
MAR-2020	0 0%	2 0%	1 10%	860 36%	9 90%	1434 60%	0 0%	93 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
APR-2020	0 0%	2 0%	0 0%	838 36%	4 80%	1412 60%	1 20%	93 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
MAY-2020	0 0%	2 0%	1 10%	834 36%	9 90%	1411 60%	0 0%	89 4%	0 0%	0 0%	0 0%	6 0%	0 0%	0 0%
JUN-2020	0 0%	2 0%	2 33%	812 35%	4 67%	1386 61%	0 0%	86 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
JUL-2020	0 0%	1 0%	0 0%	779 35%	8 100%	1359 61%	0 0%	81 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
AUG-2020	0 0%	1 0%	1 20%	749 35%	4 80%	1327 62%	0 0%	79 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
SEP-2020	0 0%	0 0%	1 33%	734 35%	2 67%	1298 61%	0 0%	79 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
OCT-2020	0 0%	0 0%	0 0%	711 34%	6 100%	1281 62%	0 0%	77 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
NOV-2020	0 0%	1 0%	0 0%	694 34%	3 100%	1270 62%	0 0%	77 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
DEC-2020	0 0%	1 0%	1 8%	677 33%	11 92%	1286 63%	0 0%	76 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
JAN-2021	0 0%	1 0%	0 0%	655 32%	5 100%	1297 64%	0 0%	71 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2021	0 0%	1 0%	0 0%	643 33%	5 100%	1262 64%	0 0%	71 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
MAR-2021	0 0%	1 0%	1 25%	621 32%	3 75%	1261 65%	0 0%	73 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
APR-2021	0 0%	1 0%	0 0%	595 31%	4 100%	1230 65%	0 0%	72 4%	0 0%	1 0%	0 0%	2 0%	0 0%	1 0%
MAY-2021	0 0%	1 0%	0 0%	589 31%	4 100%	1239 65%	0 0%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUN-2021	0 0%	1 0%	0 0%	573 31%	4 80%	1221 66%	1 20%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUL-2021	0 0%	1 0%	0 0%	561 30%	6 100%	1217 66%	0 0%	68 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
AUG-2021	0 0%	0 0%	0 0%	548 30%	2 100%	1206 66%	0 0%	66 4%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%
SEP-2021	0 0%	1 0%	0 0%	538 30%	2 100%	1186 66%	0 0%	61 3%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	0 0%	1 0%	3 100%	590 36%	0 0%	202 12%	0 0%	501 31%	0 0%	325 20%
FEB-2020	0 0%	1 0%	4 100%	558 36%	0 0%	198 13%	0 0%	483 31%	0 0%	320 21%
MAR-2020	0 0%	1 0%	4 100%	547 36%	0 0%	195 13%	0 0%	464 31%	0 0%	315 21%
APR-2020	0 0%	1 0%	6 86%	542 36%	0 0%	190 13%	0 0%	456 30%	1 14%	313 21%
MAY-2020	0 0%	1 0%	1 50%	536 36%	0 0%	193 13%	0 0%	452 30%	1 50%	305 21%
JUN-2020	0 0%	1 0%	2 100%	524 36%	0 0%	189 13%	0 0%	447 30%	0 0%	307 21%
JUL-2020	0 0%	3 0%	2 50%	507 35%	0 0%	184 13%	2 50%	438 31%	0 0%	305 21%
AUG-2020	1 100%	4 0%	0 0%	501 36%	0 0%	179 13%	0 0%	421 30%	0 0%	294 21%
SEP-2020	0 0%	5 0%	1 33%	476 35%	0 0%	174 13%	0 0%	409 30%	2 67%	293 22%
OCT-2020	0 0%	9 1%	1 100%	461 35%	0 0%	171 13%	0 0%	402 30%	0 0%	279 21%
NOV-2020	0 0%	10 1%	2 67%	451 35%	0 0%	171 13%	1 33%	393 30%	0 0%	279 21%
DEC-2020	0 0%	11 1%	2 67%	437 34%	0 0%	163 13%	0 0%	383 30%	1 33%	276 22%
JAN-2021	0 0%	11 1%	1 100%	426 34%	0 0%	164 13%	0 0%	379 30%	0 0%	272 22%
FEB-2021	0 0%	15 1%	0 0%	418 34%	0 0%	161 13%	0 0%	365 30%	0 0%	267 22%
MAR-2021	0 0%	21 2%	2 100%	419 34%	0 0%	162 13%	0 0%	365 30%	0 0%	266 22%
APR-2021	0 0%	20 2%	1 50%	409 34%	0 0%	155 13%	1 50%	359 30%	0 0%	260 22%
MAY-2021	1 20%	30 3%	3 60%	397 33%	0 0%	154 13%	0 0%	353 30%	1 20%	259 22%
JUN-2021	0 0%	41 4%	2 100%	379 32%	0 0%	155 13%	0 0%	345 30%	0 0%	251 22%
JUL-2021	0 0%	45 4%	1 100%	372 32%	0 0%	153 13%	0 0%	339 29%	0 0%	245 21%
AUG-2021	0 0%	56 5%	1 100%	366 32%	0 0%	150 13%	0 0%	337 29%	0 0%	243 21%
SEP-2021	0 0%	67 6%	3 75%	357 31%	0 0%	146 13%	0 0%	332 29%	1 25%	244 21%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	9 50%	421 10%	7 39%	2687 62%	0 0%	707 16%	0 0%	32 1%	2 11%	594 14%
FEB-2020	14 52%	602 14%	11 41%	2642 60%	2 7%	654 15%	0 0%	29 1%	0 0%	576 13%
MAR-2020	19 68%	755 17%	7 25%	2623 58%	1 4%	623 14%	1 4%	30 1%	0 0%	562 12%
APR-2020	7 50%	827 18%	6 43%	2589 57%	1 7%	607 13%	0 0%	29 1%	0 0%	544 12%
MAY-2020	10 56%	911 20%	6 33%	2554 56%	2 11%	597 13%	0 0%	27 1%	0 0%	541 12%
JUN-2020	4 31%	1022 22%	9 69%	2537 55%	0 0%	582 13%	1 8%	28 1%	0 0%	538 12%
JUL-2020	9 38%	1140 24%	10 42%	2508 54%	5 21%	549 12%	0 0%	29 1%	0 0%	527 11%
AUG-2020	10 59%	1219 26%	6 35%	2458 52%	1 6%	517 11%	0 0%	29 1%	0 0%	520 11%
SEP-2020	13 87%	1336 28%	2 13%	2440 51%	0 0%	497 10%	0 0%	29 1%	0 0%	504 11%
OCT-2020	10 59%	1444 30%	5 29%	2424 50%	0 0%	493 10%	0 0%	30 1%	2 12%	493 10%
NOV-2020	8 36%	1540 31%	9 41%	2475 50%	2 9%	480 10%	0 0%	27 1%	3 14%	489 10%
DEC-2020	10 53%	1624 33%	7 37%	2465 49%	2 11%	459 9%	0 0%	27 1%	0 0%	477 10%
JAN-2021	12 80%	1697 34%	3 20%	2461 49%	0 0%	442 9%	0 0%	27 1%	0 0%	469 9%
FEB-2021	14 64%	1774 35%	5 23%	2476 49%	3 14%	420 8%	0 0%	24 0%	0 0%	457 9%
MAR-2021	23 72%	1839 35%	9 28%	2491 48%	0 0%	418 8%	0 0%	24 0%	0 0%	454 9%
APR-2021	15 75%	1901 36%	4 20%	2504 48%	1 5%	412 8%	0 0%	22 0%	0 0%	438 8%
MAY-2021	15 65%	1980 37%	7 30%	2509 47%	0 0%	397 7%	0 0%	22 0%	1 4%	439 8%
JUN-2021	16 76%	2057 38%	4 19%	2498 47%	1 5%	387 7%	0 0%	23 0%	0 0%	440 8%
JUL-2021	13 76%	2113 39%	3 18%	2498 46%	1 6%	383 7%	0 0%	23 0%	0 0%	432 8%
AUG-2021	15 71%	2156 40%	5 24%	2488 46%	1 5%	376 7%	0 0%	23 0%	0 0%	424 8%
SEP-2021	18 75%	2198 40%	5 21%	2476 46%	1 4%	365 7%	0 0%	23 0%	0 0%	411 8%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		IV 3 drugs from IV 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2020	1617	21.98	1210	16.44	3562	48.41	55	0.75	761	10.34	153	2.08
FEB-2020	1573	21.46	1154	15.75	3643	49.71	55	0.75	757	10.33	147	2.01
MAR-2020	1540	20.85	1134	15.35	3755	50.83	57	0.77	759	10.27	142	1.92
APR-2020	1522	20.55	1129	15.24	3807	51.39	57	0.77	750	10.12	143	1.93
MAY-2020	1512	20.44	1111	15.02	3830	51.78	56	0.76	748	10.11	140	1.89
JUN-2020	1458	19.79	1084	14.71	3881	52.67	55	0.75	752	10.21	138	1.87
JUL-2020	1420	19.36	1058	14.43	3935	53.66	57	0.78	729	9.94	134	1.83
AUG-2020	1375	18.96	1026	14.14	3943	54.36	66	0.91	714	9.84	130	1.79
SEP-2020	1336	18.47	980	13.55	3998	55.27	79	1.09	710	9.82	130	1.80
OCT-2020	1308	18.00	964	13.27	4058	55.86	101	1.39	701	9.65	133	1.83
NOV-2020	1287	17.53	946	12.89	4128	56.24	159	2.17	697	9.50	123	1.68
DEC-2020	1272	17.31	924	12.58	4153	56.53	177	2.41	703	9.57	118	1.61
JAN-2021	1273	17.24	912	12.35	4191	56.76	202	2.74	693	9.39	113	1.53
FEB-2021	1232	16.70	894	12.12	4226	57.29	223	3.02	689	9.34	113	1.53
MAR-2021	1209	16.27	890	11.98	4274	57.51	246	3.31	707	9.51	106	1.43
APR-2021	1166	15.72	868	11.70	4319	58.23	273	3.68	690	9.30	101	1.36
MAY-2021	1146	15.38	858	11.51	4349	58.35	296	3.97	704	9.45	100	1.34
JUN-2021	1125	15.09	834	11.18	4371	58.62	324	4.34	705	9.45	98	1.31
JUL-2021	1106	14.81	823	11.02	4386	58.73	352	4.71	702	9.40	99	1.33
AUG-2021	1092	14.61	819	10.96	4391	58.73	377	5.04	701	9.38	96	1.28
SEP-2021	1073	14.41	814	10.93	4381	58.82	394	5.29	694	9.32	92	1.24

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2020	12	0	2	1	4	4	490
FEB-2020	19	5	1	5	3	5	320
MAR-2020	23	4	0	3	1	10	550
APR-2020	8	0	0	3	0	5	686
MAY-2020	15	1	0	3	4	7	400
JUN-2020	9	1	0	3	4	1	380
JUL-2020	12	3	0	0	2	4	500
AUG-2020	11	3	1	3	2	1	225
SEP-2020	8	3	2	1	0	0	71
OCT-2020	13	2	1	1	3	3	381
NOV-2020	11	0	1	0	2	6	710
DEC-2020	13	3	3	3	0	4	260
JAN-2021	9	1	3	0	1	2	170
FEB-2021	13	0	2	3	4	4	360
MAR-2021	24	4	5	3	5	5	280
APR-2021	9	2	1	1	1	4	370
MAY-2021	14	1	1	3	2	4	480
JUN-2021	15	4	1	3	2	4	289
JUL-2021	12	1	2	0	2	4	480
AUG-2021	12	1	1	4	2	2	300
SEP-2021	9	0	1	2	3	3	400

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2020	12525	4021
FEB-2020	12557	4039
MAR-2020	12558	4030
APR-2020	12536	4006
MAY-2020	12526	3994
JUN-2020	12503	3972
JUL-2020	12480	3939
AUG-2020	12448	3915
SEP-2020	12411	3887
OCT-2020	12389	3875
NOV-2020	12403	3876
DEC-2020	12380	3837
JAN-2021	12389	3839
FEB-2021	12381	3833
MAR-2021	12379	3822
APR-2021	12368	3809
MAY-2021	12363	3797
JUN-2021	12365	3792
JUL-2021	12387	3811
AUG-2021	12381	3817
SEP-2021	12353	3786

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved


Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7448
Sep-2021

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Sep-2021

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Sep-2021

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Sep-2021

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Sep-2021

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Sep-2021

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	8	8	7
	35-49	10	11	5
	50+	29	41	20
	Total HSDA:	47	60	32
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	73	100	59	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	403	544	304	
THOMPSON/CARIBOO/ SHUSWAP	20-34	21	21	11
	35-49	70	76	50
	50+	117	189	91
	Total HSDA:	208	286	152
Total HA:		731	990	547

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		731	990	547

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	141	195	104
Male	590	795	443

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	547	56	620	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	23	13
	5 years or more	13	10
	<5 years	11	9
	Total HSDA:	47	32
KOOTENAY BOUNDARY	10 years or more	47	37
	5 years or more	15	12
	<5 years	11	10
	Total HSDA:	73	59
OKANAGAN	10 years or more	258	188
	5 years or more	87	68
	<5 years	58	48
	Total HSDA:	403	304
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	128	97
	5 years or more	44	36
	<5 years	36	19
	Total HSDA:	208	152
Total HA:		731	547

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	456	335
	5 years or more	159	126
	<5 years	116	86
Total HA:		731	547

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	51	70	14	29
KOOTENAY BOUNDARY	76	129	25	50
OKANAGAN	229	970	56	291
THOMPSON/CARIBOO/SHUSWAP	141	536	36	132
Total:	497	1705	131	502

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	110

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	29	31	24
	35-49	98	104	66
	50+	243	334	187
	Total HSDA:	376	475	283
FRASER NORTH	20-34	118	118	73
	35-49	351	375	265
	50+	617	977	481
	Total HSDA:	1086	1470	819
FRASER SOUTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1024	1352	823
Total HA:		2486	3297	1925

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	10
	20-34	266	270	184
	35-49	757	821	578
	50+	1453	2196	1153
Total HA:		2486	3297	1925

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	608	774	454
Male	1878	2523	1471

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1925	53	640	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	233	179
	5 years or more	82	58
	<5 years	61	46
	Total HSDA:	376	283
FRASER NORTH	10 years or more	660	477
	5 years or more	240	191
	<5 years	186	151
	Total HSDA:	1086	819
FRASER SOUTH	10 years or more	621	489
	5 years or more	220	173
	<5 years	183	161
	Total HSDA:	1024	823
Total HA:		2486	1925

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1514	1145
	5 years or more	542	422
	<5 years	430	358
Total HA:		2486	1925

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries
FRASER Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	141	510	29	59
FRASER NORTH	254	1608	46	218
FRASER SOUTH	223	1657	51	492
Total:	618	3775	126	769

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	186
FRASER NORTH	669
FRASER SOUTH	461
Total:	1316

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		354	513
RICHMOND	20-34	34	35	20
	35-49	45	47	37
	50+	112	161	90
	Total HSDA:	191	243	147
VANCOUVER	0-19	10	10	9
	20-34	423	441	272
	35-49	1304	1450	932
	50+	2924	5106	2118
	Total HSDA:	4661	7007	3331
Total HA:		5206	7763	3759

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	11	11	10
	20-34	487	506	311
	35-49	1434	1590	1031
	50+	3274	5656	2407
Total HA:		5206	7763	3759

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	607	949	433
Male	4597	6812	3326
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3759	55	650	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	210	167
	5 years or more	79	64
	<5 years	65	50
	Total HSDA:	354	281
RICHMOND	10 years or more	112	85
	5 years or more	34	25
	<5 years	45	37
	Total HSDA:	191	147
VANCOUVER	10 years or more	3075	2125
	5 years or more	940	700
	<5 years	646	506
	Total HSDA:	4661	3331
Total HA:		5206	3759

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3397	2377
	5 years or more	1053	789
	<5 years	756	593
Total HA:		5206	3759

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	181	409	54	81
RICHMOND	43	297	8	91
VANCOUVER	649	11185	212	5332
Total:	873	11891	274	5504

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	75

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		339	492
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		125	171
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		773	1099
Total HA:		1237	1762	958

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	5
	20-34	120	129	79
	35-49	282	327	223
	50+	829	1300	651
Total HA:		1237	1762	958

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	219	311	168
Male	1018	1451	790

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	958	55	590	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	202	166
	5 years or more	74	56
	<5 years	63	50
	Total HSDA:	339	272
NORTH VANCOUVER ISLAND	10 years or more	84	69
	5 years or more	26	16
	<5 years	15	15
	Total HSDA:	125	100
SOUTH VANCOUVER ISLAND	10 years or more	461	326
	5 years or more	160	132
	<5 years	152	128
	Total HSDA:	773	586
Total HA:		1237	958

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	747	561
	5 years or more	260	204
	<5 years	230	193
Total HA:		1237	958

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries VANCOUVER ISLAND Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	203	902	75	198
NORTH VANCOUVER ISLAND	152	273	46	74
SOUTH VANCOUVER ISLAND	219	1870	41	562
Total:	574	3045	162	834

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	55
NORTH VANCOUVER ISLAND	41
SOUTH VANCOUVER ISLAND	123
Total:	219

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	5	5	*
	35-49	19	22	*
	50+	23	31	*
	Total HSDA:	47	58	27
NORTH WEST	20-34	*	6	0
	35-49	*	38	16
	50+	*	72	38
	Total HSDA:	72	116	54
NORTHERN INTERIOR	0-19	7	7	5
	20-34	22	24	12
	35-49	59	73	41
	50+	106	180	81
	Total HSDA:	194	284	139
Total HA:		313	458	220

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	5
	20-34	31	35	14
	35-49	102	133	70
	50+	173	283	131
Total HA:		313	458	220

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	117	171	79
Male	196	287	141

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	220	52	560	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	28	*
	5 years or more	8	*
	<5 years	11	*
	Total HSDA:	47	27
NORTH WEST	10 years or more	44	33
	5 years or more	18	13
	<5 years	10	8
	Total HSDA:	72	54
NORTHERN INTERIOR	10 years or more	95	69
	5 years or more	63	46
	<5 years	36	24
	Total HSDA:	194	139
Total HA:		313	220

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	167	118
5 years or more	89	62
<5 years	57	40
Total HA:	313	220

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	40	62	4	5
NORTH WEST	81	167	17	34
NORTHERN INTERIOR	119	478	20	185
Total:	240	707	41	224

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	20
NORTHERN INTERIOR	12
Total:	39

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	7	11	6
	KOOTENAY BOUNDARY	6	9	5
	OKANAGAN	28	45	15
	THOMPSON/CARIBOO/SHUSWAP	24	48	18
	Total HA:	65	113	44
FRASER	FRASER EAST	35	47	28
	FRASER NORTH	53	90	44
	FRASER SOUTH	83	117	63
	Total HA:	171	254	135
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	29	52	23
	RICHMOND	8	13	5
	VANCOUVER	474	890	372
	Total HA:	511	955	400
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	49	82	40
	NORTH VANCOUVER ISLAND	16	26	13
	SOUTH VANCOUVER ISLAND	43	87	31
	Total HA:	108	195	84
NORTHERN	NORTH EAST	11	15	8
	NORTH WEST	32	65	25
	NORTHERN INTERIOR	69	111	53
	Total HA:	112	191	86
Total:		967	1708	749

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	358	611	274
Male	609	1097	475

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	749	52	510	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Monthly Report

Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Monthly Report

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Monthly Report

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

